BlackRock
OLMA icon

BlackRock’s Olema Pharmaceuticals OLMA Stock Holding History

BlackRock’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.3M Buy
5,652,135
+88,875
+2% +$1.98M ﹤0.01% 2213
2025
Q4 		$139M Buy
5,563,260
+836,866
+18% +$14.9M ﹤0.01% 1902
2025
Q3 		$46.3M Buy
4,726,394
+121,285
+3% +$728K ﹤0.01% 2557
2025
Q2 		$19.6M Buy
4,605,109
+782,767
+20% +$3.49M ﹤0.01% 3039
2025
Q1 		$14.4M Buy
3,822,342
+32,510
+0.9% +$164K ﹤0.01% 3124
2024
Q4 		$22.1M Sell
3,789,832
-57,639
-1% -$576K ﹤0.01% 2985
2024
Q3 		$45.9M Sell
3,847,471
-152,047
-4% -$1.94M ﹤0.01% 2515
2024
Q2 		$43.3M Buy
3,999,518
+782,964
+24% +$8.49M ﹤0.01% 2497
2024
Q1 		$36.4M Sell
3,216,554
-47,353
-1% -$611K ﹤0.01% 2636
2023
Q4 		$45.8M Buy
3,263,907
+1,021,018
+46% +$13.7M ﹤0.01% 2529
2023
Q3 		$27.7M Sell
2,242,889
-90,411
-4% -$922K ﹤0.01% 2752
2023
Q2 		$21.1M Buy
2,333,300
+1,337,123
+134% +$8.07M ﹤0.01% 3009
2023
Q1 		$3.46M Sell
996,177
-47,018
-5% -$192K ﹤0.01% 3801
2022
Q4 		$2.56M Sell
1,043,195
-258,731
-20% -$755K ﹤0.01% 4024
2022
Q3 		$3.59M Sell
1,301,926
-3,578
-0.3% -$15.2K ﹤0.01% 3902
2022
Q2 		$5.31M Sell
1,305,504
-1,247,445
-49% -$3.96M ﹤0.01% 3791
2022
Q1 		$10.9M Buy
2,552,949
+254,785
+11% +$1.4M ﹤0.01% 3535
2021
Q4 		$21.5M Sell
2,298,164
-41,811
-2% -$866K ﹤0.01% 3231
2021
Q3 		$64.5M Buy
2,339,975
+870,796
+59% +$23.5M ﹤0.01% 2496
2021
Q2 		$41.1M Buy
1,469,179
+16,159
+1% +$460K ﹤0.01% 2830
2021
Q1 		$48.2M Buy
1,453,020
+768,311
+112% +$32.9M ﹤0.01% 2638
2020
Q4 		$32.9M Buy
+684,709
New +$32.1M ﹤0.01% 2733

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock's OLMA Position: Q1 2026 in Review

BlackRock increased its Olema Pharmaceuticals (OLMA) stake by 1.6% in Q1 2026, buying an estimated $1.98M and bringing the position to 5,652,135 shares worth $84.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2213.

BlackRock first reported a position in OLMA in Q4 2020 and has held it in 22 quarters since. The position peaked at $139M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • BlackRock held 5,652,135 shares of Olema Pharmaceuticals worth $84.3M as of Q1 2026.
  • BlackRock bought 88,875 Olema Pharmaceuticals shares in Q1 2026, an estimated $1.98M.
  • Olema Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2213 holding.
  • BlackRock first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • BlackRock's Olema Pharmaceuticals position peaked at $139M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.